Anti‐RH1 alloimmunization: At what maternal antibody threshold is there a risk of severe fetal anemia?
Transfusion · 2023
DOI: 10.1111/trf.17264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2023. Verfasst von Louise Ghesquière und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Jeanne de Flandre Hospital, CHU Lille, Lille, France. Hauptthemen laut MEDLINE: Fetal Diseases, Anemia, Hemolytic, Autoimmune, Rh Isoimmunization. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
To define a threshold of maternal antibodies at risk of severe fetal anemia in patients followed for anti‐RH1 alloimmunization (AI). Study, Design, and Methods We conducted a retrospective study of patients followed for anti‐RH1 AI at the Lille University Hospital. The first group, severe anemia, included patients who received one or more in utero transfusions (IUT) or who were induced before 37 weeks of pregnancy for suspected severe fetal anemia. The second group, absence of severe anemia, corresponded to patients without intervention during pregnancy related to AI. Sensitivities, specificities, and positive and negative predictive values for screening for severe fetal anemia were calculated for the antibody thresholds of 3.5 and 5 IU/ml for the quantification.
Results
Between 2000 and 2018, 207 patients were included 135 in the severe anemia group and 72 in the no severe anemia group. No severe anemia was observed for an antibody titer below 16. For an antibody threshold of 3.5 IU/ml, the sensitivity was 98.2%, with 30.2% false positives. All severe anemias were detected in the second trimester; two cases of severe anemia were not detected in the third trimester. For an antibody threshold of 5 IU/ml, the sensitivity was lower at 95.6%, with five cases of severe anemia not detected.
Conclusion
The antibody threshold of 3.5 IU/ml for the quantification and 16 for the titration allow targeting patients requiring close monitoring by an experienced team in case of anti‐RH1 AI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics, Jeanne de Flandre Hospital, CHU Lille, Lille, France.
- Univ. Lille, CHU Lille, ULR 2694 - METRICS - Evaluation des Technologies de Santé et des Pratiques Médicales, Lille, France.
- Department of Biostatistics, CHU Lille, Lille, France.
- French Blood Establishment, Nord Pas de Calais, France.
Zitieren
APA
Ghesquière, L., Leroy, J., Deken, V., Tournier, A., Vaast, P., Subtil, D., Delsalle, A., Alluin, G., Garabedian, C., & Houfflin-Debarge, V. (2023). Anti‐RH1 alloimmunization: At what maternal antibody threshold is there a risk of severe fetal anemia?. Transfusion. https://doi.org/10.1111/trf.17264
Vancouver
Ghesquière L, Leroy J, Deken V, Tournier A, Vaast P, Subtil D, et al. Anti‐RH1 alloimmunization: At what maternal antibody threshold is there a risk of severe fetal anemia?. Transfusion. 2023. doi:10.1111/trf.17264
BibTeX
@article{Ghesquire2023,
author = {Ghesquière, Louise and Leroy, Julie and Deken, Valérie and Tournier, Alexane and Vaast, Pascal and Subtil, Damien and Delsalle, Anne and Alluin, Gauthier and Garabedian, Charles and Houfflin-Debarge, Véronique},
title = {Anti‐RH1 alloimmunization: At what maternal antibody threshold is there a risk of severe fetal anemia?},
journal = {Transfusion},
year = {2023},
doi = {10.1111/trf.17264}
}
EUVIMED